Hedge Funds Investors in TScan Therapeutics, Inc. (NASDAQ:TCRX) See US$52m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
Hedge Funds Investors in TScan Therapeutics, Inc. (NASDAQ:TCRX) See US$52m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
Key Insights
主要见解
- Given the large stake in the stock by institutions, TScan Therapeutics' stock price might be vulnerable to their trading decisions
- A total of 6 investors have a majority stake in the company with 50% ownership
- Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business
- 考虑到机构股东所持有的大量股份,TScan Therapeutics的股价可能会受到他们的交易决策的影响。
- 共有6名投资者拥有该公司的多数股权,拥有50%的所有权。
- 分析师预测以及所有者数据可以给我们提供有关业务前景的强烈想法。
To get a sense of who is truly in control of TScan Therapeutics, Inc. (NASDAQ:TCRX), it is important to understand the ownership structure of the business. We can see that hedge funds own the lion's share in the company with 46% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
为了了解TScan Therapeutics, Inc. (NASDAQ:TCRX)真正的掌控者,理解业务的所有权结构非常重要。我们可以看到,对于该公司46%的所有权被对冲基金所持有,也就是说,该群体面临着最大的上行潜力(或下行风险)。
Losing money on investments is something no shareholder enjoys, least of all hedge funds investors who saw their holdings value drop by 14% last week. However, the 146% one-year return to shareholders may have helped lessen their pain. We would assume however, that they would be on the lookout for weakness in the future.
任何股东都不希望在投资上亏钱,尤其是对冲基金的投资者们,他们上周看到自己的持股价值下跌了14%,这使得他们痛苦万分。不过,一年146%的股东回报率可能有所缓解。但是我们认为,他们肯定会对未来的形势保持警惕。
In the chart below, we zoom in on the different ownership groups of TScan Therapeutics.
下图展示了TScan Therapeutics不同所有权组的所有权情况。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240628/0-46d6bf0282374d580d52392fd54bd53a-0-69926e334b2b954cbfe297bbda3b18d6.png/big)
What Does The Institutional Ownership Tell Us About TScan Therapeutics?
机构股东持股信息对于TScan Therapeutics有何启示?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
机构通常在向自己的投资者报告时会针对一个基准进行衡量,因此一旦某只股票被纳入主要指数,他们通常会更加热衷于该股票。我们预计大多数公司都会有一些机构在登记簿上,尤其是那些正在增长的公司。
TScan Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at TScan Therapeutics' earnings history below. Of course, the future is what really matters.
TScan Therapeutics已经拥有许多股东,其中不乏机构股东占据相当大的股份,这表明他们在专业投资者中具有一定的信誉。但是我们不能仅仅依靠这个事实,因为机构有时候也会做出糟糕的投资,就像每个人一样。如果多个机构同时改变他们对某支股票的看法,你可能会看到股价快速下跌。因此,值得看一看TScan Therapeutics以下的收益历史。当然,未来才是真正的关键。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240628/0-46d6bf0282374d580d52392fd54bd53a-1-d14d99100188f8c7d80388cdc91fcad5.png/big)
It would appear that 46% of TScan Therapeutics shares are controlled by hedge funds. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Looking at our data, we can see that the largest shareholder is Baker Bros. Advisors LP with 13% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 9.9% and 9.5%, of the shares outstanding, respectively.
看来TScan Therapeutics的46%股权由对冲基金控制。这引起了我的关注,因为对冲基金有时会试图影响管理层或促使公司做出改变,以创造近期的股东价值。从我们的数据来看,最大的股东是Baker Bros. Advisors LP,持有该公司13%的流通股。同时,第二和第三大股东分别持有该公司流通股的9.9%和9.5%。
We also observed that the top 6 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.
我们还观察到,前6大股东持有超过一半的股份登记簿,有一些较小的股东来平衡较大股东的利益。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
尽管研究公司的机构持股可以增加您的研究价值,但研究分析师的建议也是一个好习惯,以更深入地了解股票的预期表现。有相当数量的分析师关注该股,因此了解他们对未来的总体观点可能很有用。
Insider Ownership Of TScan Therapeutics
TScan Therapeutics内部股权
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间有所不同。我们的数据反映了个人内部人员,至少捕捉到董事会成员的记录。公司管理人员向董事会报告,后者应该代表股东的利益。值得注意的是,有时高级管理人员自己也在董事会中。
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多数人认为内部所有权是积极的,因为它可以表示董事会与其他股东的利益相一致。但是,在某些场合下,这个团体的权力过于集中。
Our information suggests that TScan Therapeutics, Inc. insiders own under 1% of the company. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. It appears that the board holds about US$2.6m worth of stock. This compares to a market capitalization of US$323m. We generally like to see a board more invested. However it might be worth checking if those insiders have been buying.
我们了解的信息表明,TScan Therapeutics, Inc.内部人员持有的公司股份不到1%。但是我们注意到,内部人员可能通过私人公司或其他公司结构间接拥有利益。看起来,董事会持有价值约260万美元的股票,而市值为3.23亿美元。我们通常希望看到董事会的投资更多一些。但值得检查的是,那些内部人员是否一直在购买股票。
General Public Ownership
一般大众所有权
With a 13% ownership, the general public, mostly comprising of individual investors, have some degree of sway over TScan Therapeutics. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
拥有13%股权的普通公众,主要由个人投资者组成,在TScan Therapeutics拥有一定的影响力。尽管拥有相当大的所有权,但如果决策与其他大的股东不符,可能无法改变公司政策。
Private Company Ownership
私有公司的所有权
Our data indicates that Private Companies hold 4.1%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
我们的数据显示,私人公司持有该公司4.1%的股份。私人公司可能是相关方。有时内部人员通过控股私人公司而拥有公开公司的利益,而不是以个人身份拥有。虽然很难得出任何概括性结论,但这值得进一步研究。
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand TScan Therapeutics better, we need to consider many other factors. For instance, we've identified 4 warning signs for TScan Therapeutics (1 is significant) that you should be aware of.
考虑拥有公司股份的不同群体总是值得思考的。但要更好地了解TScan Therapeutics,我们需要考虑许多其他因素。例如,我们已经确定了TScan Therapeutics的4个警示信号(其中1个很重要),您应该知悉。
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
但最终,决定该业务所有者将获得多大利益的是未来而非过去。因此,我们认为最好查看此免费报告,以了解分析师是否预测更光明的未来。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或电邮 editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,也可以发送电子邮件至editorial-team@simplywallst.com